Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 1;107(5):1018-1019.
doi: 10.3324/haematol.2022.280857.

Proteasome inhibition: the dawn of novel therapies in multiple myeloma

Monika Engelhardt  1 , Johannes Moritz Waldschmidt  2 , Ralph Wäsch  2
Affiliations

Proteasome inhibition: the dawn of novel therapies in multiple myeloma

Monika Engelhardt et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proteosome inhibition. (A) Mechanism of proteasome inhibition. (B) APEX trial randomizing 669 patients (pts) 1:1 to bortezomib (Bz)/dexamethasone (D) (VD) vs. D alone and the achievements evolving from this pivotal trial. (C) Key clinical trials that led to Food and Drug Adminstration (FDA) and European Medicines Agency (EMA) approval of various novel agents (NA). The proteosome inhibitor (PI) Bz in the APEX trial was established as one fundamental NA and was the clinical study that led others to follow and likewise achieve clinical significance in multiple myeloma (MM). Dex: dexamethasone; RRMM: relapsed/refractory MM (RRMM).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lohr JG, Stojanov P, Carter SL, et al. . Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101. - PMC - PubMed
    1. Richardson PG, Sonneveld P, Schuster MW, et al. . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-2498. - PubMed
    1. Orlowski RZ. The ubiquitin proteasome pathway from bench to bedside. Hematology Am Soc Hematol Educ Program. 2005;220-225. - PubMed

MeSH terms